Emcure Pharmaceuticals has launched Poviztra, a semaglutide injection indicated for weight management, in the Indian market. The company disclosed the launch through a stock exchange filing dated December 22, 2025.
The product has been commercially introduced across India and will be sold as a once-weekly injectable therapy.
Poviztra has been priced starting at ₹8,790 per month, which covers 4 weekly doses. The drug will be available in 5 strengths, 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg and a 2.4 mg maintenance dose. It will be administered through a pre-filled pen device, which is standard for weekly injectable formulations.
Emcure stated that it is the 1st Indian pharmaceutical company to exclusively distribute and commercialise Poviztra in India. The product is positioned as a 2nd brand of Novo Nordisk’s semaglutide injection for weight management.
Semaglutide-based drugs are already marketed in several countries and have been in clinical and commercial use for nearly a decade.
According to information shared by the company, semaglutide is supported by data from the STEP and SELECT clinical trial programmes. Globally, the molecule has recorded around 38 million patient-years of exposure. Clinical trial results have shown weight loss exceeding 20% in a significant number of patients treated with the drug.
Poviztra is indicated as an adjunct to reduced-calorie diets and increased physical activity for adults with a body mass index (BMI) of 30 kg/m² or higher. It is also approved for adults with a BMI of 27 kg/m² or higher who have at least one weight-related condition, including hypertension, type 2 diabetes or dyslipidaemia.
As per the filing, the drug is additionally indicated to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease who are overweight or obese.
As of December 23, 2025, 10:13 am, Emcure Pharmaceuticals share price was trading at ₹1,392.40, a 0.96% increase from the previous closing price.
Read More: Ambuja Cement Share Price in Focus as ACC and Orient Cement Merger Gets Board Approval!
The launch of Poviztra adds another semaglutide-based prescription option to India’s weight management market, where demand for long-term obesity treatment continues to increase.
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in the securities market are subject to market risks, read all the related documents carefully before investing.
Published on: Dec 23, 2025, 11:33 AM IST
Team Angel One
We're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
EN